Assessment of the bioequivalence of two nelfinavir tablet formulations under fed and fasted conditions in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 43, Issue 3, 2005, Pages 154-162

  Kaeser, Benoite ^a   Charoin, J E ^a   Gerber, M ^b   Oxley, P ^c   Birnboeck, H ^a   Saiedabadi, N ^c   Banken, L ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Inst de Pharmacol Clinique Roche   (France)

^c ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Bioequivalence; Influence of food; Nelfinavir; Pharmacokinetics

Indexed keywords

DRUG METABOLITE; NELFINAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CALORIC INTAKE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG FORMULATION; DRUG USE; FEEDING; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MEAL; NORMAL HUMAN; OPEN STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL MODEL; TABLET; VALIDATION PROCESS;

EID: 15844385617     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP43154     Document Type: Article

References (20)

1. Bardsley-Elliot A, Plosker GL 2000 Nelfinavir, an update on its use in HIV infection. Drugs 59: 581-620
2. Barry M, Gibbons S, Back D et al 1997 Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 32: 194-209
3. Carr A, Miller J, Law M 1999 A syndrome of lipodystrophy (LD), lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue reverse transcriptase inhibitor therapy: contribution to PI-related LD syndrome (Abstract no. 11). First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego
4. Chen Mei-Ling, Shah V, Patnaik R et al 2001 Bioavailability and bioequivalence: an FDA regulatory overview. Pharm, Res 18: 1645-1655
5. CPMP 2001 Note for guidance on the investigation of bioavailability and bioequivalence. London, July 26, 2001
6. El-Tahtawy AA, Jackson AJ, Ludden TM 1994 Comparison of single dose and multiple dose pharmacokinetics using clinical bioequivalence data and Monte Carlo Simulations. Pharm Res 11: 1330-1336
7. EMEA 2004 The European Agency for the Evaluation of Medicinal Products CPMP/950/97 European Public Assessment Report EPAR. VIRACEPT (INN: Nelfinavir from URL: www.emea.eu.int/emea.html (accessed February 2004)
8. FDA Food and Drug Administration 2001 Guidance on statistical approaches to establishing bioequivalence. Centre for Drug Evaluation and Research, Rockville, MD, USA
9. Flesch G, Tudor D, Souppart C, D'Souza JD, Hossain M 2003 Oxcarbazepine final market image tablet formulation bioequivalence study after single administration and at steady state in healthy subjects. Int J Clin Pharmacol Ther 41: 299-308
10. Gibaldi M, Perrier D 1982 Pharmacokinetics. Second Edition. Marcel Dekker, New York, pp 445-449
11. Harwell JI, Morris A, Watson-Bitar MA 1998 Adherence and outcomes of patients taking nelfinavir three times versus twice daily (abstract). Clin Infect Dis 27: 1006
12. Jarvis B, Faulds D 1998 Nelfinavir: a review of its therapeutic efficacy in HIV infection. Drugs 56: 147-167
13. Kotler DP 1999 Summary Report. First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; San Diego
14. Kurowski M, Kaeser B, Sawyer A, Popescu M, Mroziekiewics A, Arslan A, Staszewski S 2002 Limited effect of food composition on the pharmacokinetics of nelfinavir administered twice daily. Eur J Med Res 7: 453-456
15. Singh BN 1999 Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 37: 213-255
16. Skowron G, Leoung G, Kerr B, Dusek A, Anderson R, Beebe S, Grosso R 1998 Lack of pharmacokinetic interaction between nelfinavir and nevirapine. AIDS 12: 1243-1244
17. US Approved Labelling for Viracept 2000 Physician's Desk Reference (electronic library from URL: www.pdrel.com (accessed July 2004)
18. WinNonlin Professional WinNonlin Version 3.3 2000 Scientific Consulting Inc., Mountain View, California 94040, USA
19. Zhang MH, Pithavala YK, Lee CA 1998 Apparent genetic polymorphism in nelfinavir metabolism: evaluation of clinical relevance (abstract No 264). Proceedings of the 12th International Symposium on Microsomes and Drug Oxidations. July 20-24; Montpellier, France
20. Zhang KE, Wu E, Patick AK, Kerr B, Zorbas M, Lankford A, Kobayashi T, Maeda Y, Sheity B, Webber S 2001 Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother 45: 1086-1092